Zoetis Inc. (ZTS) To Go Ex-Dividend on July 20th

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Wednesday, May 20th. Shareholders of record on Monday, July 20th will be paid a dividend of 0.53 per share on Tuesday, September 1st. This represents a c) annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th.

Zoetis has increased its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Zoetis to earn $7.40 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 28.6%.

Zoetis Price Performance

ZTS opened at $80.13 on Friday. Zoetis has a 12-month low of $72.38 and a 12-month high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The business’s fifty day simple moving average is $108.88 and its 200-day simple moving average is $118.92. The company has a market capitalization of $33.59 billion, a price-to-earnings ratio of 13.29, a PEG ratio of 1.30 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the company posted $1.48 EPS. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts anticipate that Zoetis will post 6.88 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.